Podium to Practice: ESMO® 2025 – Lung: IDeate-Lung01
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
2760MO – Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01
https://play.libsyn.com/embed/episode/id/38773380/height/192/theme/modern/size/large/thumbnail/no/custom-color/147cb8/time-start/00:00:00/playlist-height/200/direction/backward/hide-subscribe/yes/hide-share/yes/font-color/FFFFFF
Studies/trials discussed:
2760MO – Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01
199 Bay Street #4000
Toronto, ON M5L 1A9
©2026 OncologyEducation a Think Research company. All rights reserved. Privacy Policy. Privacy Notice. Accessibility Statement. Cookies Policy.
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.